Spring Co-Op, Oncology Research
Boehringer Ingelheim
Summary
Boehringer Ingelheim is currently seeking a talented and innovative Spring Co-Op candidate to join the Immune Regulation team within the Oncology Research department located at our Ridgefield CT facility.
Job description
As an Immune Regulation Co-Op, you will collaborate with scientists on in vitro experiments in the field of cancer immunology. The tumor microenvironment (TME) contains a complex network of suppressive immune and stromal cells, soluble mediators, and metabolic constraints that collectively inhibit anti-tumor immunity. In vitro immune assays are useful for evaluating immune cell activation, they often fail to recapitulate the suppressive conditions present within solid tumors. This co-op project aims to develop and establish functional immune suppression assays that mimic key components of the TME. These assays will provide translational platforms for evaluating novel immunomodulatory therapeutics and identifying mechanisms that restore anti-tumor immune function.
Duties & Responsibilities
- Developing and refining tumor tissue dissociation protocols
- Developing tumor microenvironment-mimetic immune suppression assays
- Establishing and optimizing tumor cell killing assays
Desired Skills, Experience and Abilities
- Strong scientific understanding and interest in one or more of the following: immunology, oncology, and cell biology
- Previous experience in cell line or primary cell culture is required, preferably cancer cells, T cells and/or myeloid cells
- Hands-on skills in relevant in vitro assay (FACS, ELISA/MSD, and/or immune cell isolation)
- CRISPR validation and experience in vitro system setup such as tumor cell killing assays is a plus
- Ability to troubleshoot both individually and as part of a team
- Strong writing, excellent record keeping and oral communication skills
- Must enjoy working in a multi-disciplinary, inquisitive, open-minded and collaborative environment
- Additional skills and interests that demonstrate soft skills are highly encouraged
Requirements
- Must be a current Master's or Ph.D degree student in good academic standing
- Student must be enrolled at an accredited college or university for the duration of the co-op
- Overall cumulative minimum GPA from last completed quarter/semester 3.0 GPA (on a 4.0 scale) preferred
- Major or minor in related field of co-op: immunology, oncology, cell biology
- Graduate and advanced degree students must have completed at least 9 credit hours at current college or university
- Must be legally authorized to work in the United States without restriction
- Must be willing to take a drug test and post-offer physical (if required)
- Must be 18 years of age or older
- Previous experience in cell line or primary cell culture is required, preferably cancer cells, T cells and/or myeloid cells
- Hands-on skills in relevant in vitro assay (FACS, ELISA/MSD, and/or immune cell isolation)
- CRISPR validation and experience in vitro system setup such as tumor cell killing assays is a plus
- Strong scientific understanding and interest in one or more of the following: immunology, oncology, and cell biology
- Ability to troubleshoot both individually and as part of a team
- Strong writing, excellent record keeping and oral communication skills
- Must enjoy working in a multi-disciplinary, inquisitive, open-minded and collaborative environment
Benefits
- Medical Coverage
- Paid Time Off
- Paid Holidays
- Disability Insurance
- Life Insurance
- Company-Sponsored Benefits
Company overview
Boehringer Ingelheim is a leading global research-driven biopharmaceutical company founded in 1885 and headquartered in Ingelheim am Rhein, Germany. As one of the world's top 20 pharmaceutical companies and the largest privately-owned pharmaceutical firm, it operates across three main business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. The company focuses on developing innovative therapies for diseases with high unmet medical needs, including cardiometabolic diseases, oncology, respiratory diseases, immunology, central nervous system disorders, and retinal health. With over 54,500 employees across 78 countries, Boehringer Ingelheim generated approximately €26.8 billion in revenue in 2024. The company maintains a strong research and development network with facilities in Germany, the United States, Austria, Japan, and Switzerland, investing significantly in advancing treatments for both human and animal health. Notable products include Jardiance (empagliflozin) for diabetes, Ofev (nintedanib) for pulmonary fibrosis, Spiriva (tiotropium) for respiratory conditions, and Pradaxa (dabigatran) for anticoagulation therapy.